Scarica l'app Stockscreener
3.50
0.00%
0.00
Precedente Chiudi:
$3.50
Aprire:
$3.51
Volume 24 ore:
171.50K
Relative Volume:
0.20
Capitalizzazione di mercato:
$114.66M
Reddito:
-
Utile/perdita netta:
$-21.24M
Rapporto P/E:
-4.1771
EPS:
-0.8379
Flusso di cassa netto:
$-22.47M
1 W Prestazione:
+7.03%
1M Prestazione:
-6.17%
6M Prestazione:
+17.45%
1 anno Prestazione:
-36.25%
Intervallo 1D:
$3.3601
$3.7498
Intervallo di 1 settimana:
$3.2153
$3.7498
Portata 52W:
$1.14
$7.47
Skye Bioscience Inc Stock (SKYE) Company Profile
Nome
Skye Bioscience Inc
Settore
Industria
Telefono
(858) 410-0266
Indirizzo
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Confronta SKYE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
0.95 | 1.26B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.50 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.60 | 110.24M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1646 | 351.80M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.23 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-15 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | William Blair | Outperform |
| 2024-09-30 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-09 | Iniziato | Craig Hallum | Buy |
| 2024-05-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-04-12 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Skye Bioscience Inc Borsa (SKYE) Ultime notizie
Skye Bioscience (NASDAQ:SKYE) Upgraded at Evercore ISI - MarketBeat
Altium Capital Management LLC Trims Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - MarketBeat
Will Skye Bioscience Inc. Bounce From 52 Week LowJuly 2025 Summary & Expert Curated Trade Ideas - 선데이타임즈
Skye Bioscience's Nimacimab: A New Frontier in Obesity Treatment and a Strategic Buy Opportunity - AInvest
Skye initiated at overweight at Evercore on obesity asset nimacimab - MSN
Evercore ISI Group initiates Skye Bioscience coverage with Outperform, $10 PT. - AInvest
Skye Bioscience Earnings Call: Positive Outlook Amid Challenges - MSN
Evercore Initiates SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Announces Target Price $10 - 富途牛牛
Evercore starts Skye Bioscience at Outperform on nimacimab potential - MSN
Will Skye Bioscience Inc. Hold Gains Into CloseLong Setup & Free Accurate Trade Setup Notifications - kangso.co.kr
Live Scanner Shows Breakout on Skye Bioscience Inc.July 2025 Spike Watch & High Yield Equity Trading Tips - newsyoung.net
Craig-Hallum Sticks to Their Buy Rating for Skye Bioscience (SKYE) - The Globe and Mail
Why Skye Bioscience Inc. stock attracts strong analyst attentionValue Into Profit Opportunities - sisaissue.com
Craig-Hallum Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating - 富途牛牛
Skye Bioscience's 2025Q2 Earnings Call: Unraveling Key Contradictions in Clinical Trial Insights and Drug Efficacy - AInvest
Skye Bioscience Q2 2025 slides: Nimacimab targets obesity treatment gaps By Investing.com - Investing.com Nigeria
Skye Bioscience signals late Q3/early Q4 top-line Phase IIa results as nimacimab advances obesity treatment platform - MSN
Skye Bioscience Q2 2025 slides: Nimacimab targets obesity treatment gaps - Investing.com India
Oppenheimer Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $17 - 富途牛牛
Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
Skye Bioscience Inc (SKYE) Q2 2025 Earnings Call Highlights: Promising Trial Progress Amid ... - Yahoo Finance
Skye Bioscience Inc (SKYE) Q2 2025 Earnings Call Highlights: Promising Trial Progress Amid ... By GuruFocus - Investing.com Canada
Earnings call transcript: Skye Bioscience Q2 2025 sees R&D surge, stock dips - Investing.com Australia
Skye Bioscience shares rise 6.48% premarket after Q2 2025 earnings call. - AInvest
Skye Bioscience Releases Q2 2025 Financial Results - TipRanks
William Blair Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating - 富途牛牛
Skye Bioscience Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Transcript : Skye Bioscience, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update - The Manila Times
Skye Bioscience : Corporate Presentation (250807 Skye Investor Deck) - MarketScreener
Skye Bioscience Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Skye Bioscience SKYE 2025Q2 Earnings Preview Upside Potential Driven by Analyst Forecasts - AInvest
We Think Skye Bioscience (NASDAQ:SKYE) Needs To Drive Business Growth Carefully - Yahoo Finance
What makes Skye Bioscience Inc. stock price move sharplyBuild a balanced portfolio for long-term success - Jammu Links News
How volatile is Skye Bioscience Inc. stock compared to the marketSky-high return potential - Jammu Links News
Is Skye Bioscience Inc. a good long term investmentMaximize gains with proven stock analysis - Jammu Links News
What drives Skye Bioscience Inc. stock priceAchieve rapid wealth accumulation through smart investing - Jammu Links News
What are analysts’ price targets for Skye Bioscience Inc. in the next 12 monthsUnlock powerful portfolio management tools - Jammu Links News
Skye Bioscience Shares Are Trading Higher After the Company Announced the Debut of Its "Anatomy of Progress" Nimacimab Development Update Video Series and Availability of Presentations Related to the Development of Its Anti-obesity Drug, Nimacimab - 富途牛牛
Why is Skye Bioscience Inc. stock attracting strong analyst attentionCapitalize on emerging trends for profits - Jammu Links News
What is the risk reward ratio of investing in Skye Bioscience Inc. stockGet daily expert analysis for smarter investing - Jammu Links News
Is Skye Bioscience Inc. stock overvalued or undervaluedAchieve consistent profits with expert advice - Jammu Links News
Is it the right time to buy Skye Bioscience Inc. stockMaximize portfolio value with smart investment plans - Jammu Links News
When is Skye Bioscience Inc. stock expected to show significant growthFree Stock Selection - Jammu Links News
How does Skye Bioscience Inc. compare to its industry peersAchieve breakthrough performance with smart picks - Jammu Links News
Should I hold or sell Skye Bioscience Inc. stock in 2025Build a strong portfolio for long-term success - Jammu Links News
Is Skye Bioscience Inc. a growth stock or a value stockHarness the power of proven investment plans - Jammu Links News
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Skye Bioscience Inc Azioni (SKYE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Skye Bioscience Inc Azioni (SKYE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Diep Tuan Tu | Chief Development Officer |
Nov 15 '24 |
Sale |
5.55 |
85 |
472 |
101,748 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 18 '24 |
Sale |
4.99 |
43,206 |
215,598 |
166,342 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 15 '24 |
Sale |
5.55 |
190 |
1,054 |
209,548 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 18 '24 |
Sale |
4.99 |
82,546 |
411,905 |
329,823 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 15 '24 |
Sale |
5.55 |
364 |
2,020 |
412,369 |
| Grayson Paul A. | Director |
Nov 18 '24 |
Sale |
4.99 |
86,244 |
430,358 |
259,701 |
| Grayson Paul A. | Director |
Nov 15 '24 |
Sale |
5.55 |
307 |
1,704 |
345,945 |
0.95%
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):